Mindray Displays New Generation Benchtop Cellular Analysis Line
|
By LabMedica International staff writers Posted on 31 Jan 2019 |

Image: The CAL 6000 benchtop cellular analysis line (Photo courtesy of Mindray).
Mindray (Shenzhen, China) exhibited its new generation benchtop cellular analysis line at MedLab Middle East, an international platform for laboratory management and medicine that brought together more than 700 exhibitors and over 35,000 professionals. MedLab Middle East 2019 took place at the Dubai International Convention and Exhibition Centre, Dubai, UAE from the 4th to the 7th of February.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Among Mindray’s latest innovations displayed at MedLab Middle East 2019 was CAL 6000, a benchtop cellular analysis line that connects two units of BC-6000 or BC-6200 auto hematology analyzers and one unit of SC-120 auto slide maker & stainer. The compact workstation helps save more laboratory space while delivering a fast throughput of up to 220 samples and 120 slides per hour. It provides automated body fluids test results, and is equipped with labXpert data management software for automatic sample validation and analysis.
At MedLab Middle East 2019, Mindray also exhibited the CL-900i chemiluminescence immunoassay analyzer, which has an industry-leading small benchtop footprint, a throughput of up to 180 tests per hour and 15 reagent positions. The CL-900i is a state-of-the-art system that is compact, fast and accurate, offering automation and reliable performance to ensure quality testing results with minimal hands-on time.
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more









